Galapagos and Celera Genomics sign gene function analysis agreement

21-Jun-2005

Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera to analyze gene function in human cells and validate potential drug targets. Galadeno will receive payments related to its services and technology.

Under the terms of the agreement, Galadeno will construct recombinant adenoviruses harboring genes selected by Celera. These custom-made viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways.

Other news from the department business & finance

These products might interest you

Blotting standards and reagents

Blotting standards and reagents by Cytiva

Western blotting standards and reagents

Blotting the course to effective detection of proteins from sample preparation to analysis

reagents
Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Greener Alternative Products

Greener Alternative Products by Merck

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
Loading...

Most read news

More news from our other portals